Skip to Content
  • Revenues ($M)
    $9,256
  • Revenue Percent Change
    20.7%
  • Profits ($M)
    $1,602
  • Profits Percent Change
    -19.9%
  • Assets ($M)
    $27,053
  • Employees
    6,971
  • Market Value — as of March 31, 2016 ($M)
    $78,237
  • Previous Rank
    369
  • Morning Consult Brand Index
    C

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Mark J. Alles
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Summit, NJ
Websitehttp://www.celgene.com
Years on Fortune 500 List5
Employees6,971

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$9,25620.7%
Profits ($M)$1,602-19.9%
Assets ($M)$27,053-
Total Stockholder Equity ($M)$5,919-
Market Value — as of March 31, 2016 ($M)$78,237-

Profit Ratios

Profit as % of Revenues17.3%
Profits as % of Assets5.9%
Profits as % of Stockholder Equity27.1%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.94
EPS % Change (from 2014)-18.8%
EPS % Change (5 year annual rate)15.6%
EPS % Change (10 year annual rate)35.9%

Total Return

Total Return to Investors (2015)7.1%
Total Return to Investors (5 year, annualized)32.3%
Total Return to Investors (10 year, annualized)22.1%